IMPROVING STROKE OUTCOMES: NEW TARGETS AND THERAPIES
Funder
National Health and Medical Research Council
Funding Amount
$7,212,064.00
Summary
Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using ....Previously we established a unique collaboration of researchers from the basic and clinical sciences.. The main aim of this ' vertically integrated ' model was to develop new therapies to improve stroke outcomes. We developed a system to identify ' off-the-shelf ' compounds which protect the brain after stroke onset. This involves data assimilation (meta-analysis) in a unique way, an approach which has attracted attention internationally. We are also completing an important clinical trial using the clot dissolving agent tPA to extend the time during which the drug may be effective beyond the three-hours currently used. In the next phase of our program we plan to expand the basic science component to identify parts of brain cells (axons and dendrites) which may yield important information about new drugs to protect the brain. We will use our novel summary data technique to test drugs in animal models more appropriate to the human stroke paradigm than have been used in the past In clinical studies we will follow our theme of identifying new targets for therapy using sophisticated PET and MRI imaging techniques, both in patients who are at great risk of stroke recurrence after a minor warning stroke and those with stroke caused by bleeding within the brain. These studies will provide information about predictors of recurrent and worsening stroke which may be modified by new therapies. The final stage in identifying new therapies is the Phase III clinical trial. We will complete one of these in which the most appropriate drug preventing further strokes in a major new stroke subtype will be identified. Toward the end of the program, we will commence phase 3 studies of drugs we have selected as being most likely to protect the brain based on our animal experiments. The main benefit of this unique collaborative research model is to efficiently identify new therapies to reduce the burden of stroke, currently the second most common cause of death globally.Read moreRead less
REDucing Delays In Aneurysmal Subarachnoid Haemorrhage: The REDDISH Study
Funder
National Health and Medical Research Council
Funding Amount
$436,022.00
Summary
Aneurysmal subarachnoid haemorrhage (aSAH) is a rare form of stroke that kills at least 30% of sufferers within 1 month. Outcome can be improved through quickly receiving medical care but many people do not and this likely contributes to the poor outcomes. The REDucing Delays In Subarachnoid Haemorrhage (REDDISH) study will look at cases of aSAH across Tasmanian and Victoria so that we can understand the factors that contribute to delays in treatment and ultimately improve outcomes.
Evaluating Cancer Screening: Context, Evidence, Values And Ethics
Funder
National Health and Medical Research Council
Funding Amount
$572,460.00
Summary
The research and clinical communities are divided over whether certain forms of cancer screening do more harm than good. This project asks: What is the right thing to do about cancer screening now? Using robust qualitative methodologies, we will study real cases of cancer screening and analyse their ethical implications. Drawing on this data and analysis, we will produce tools to help policy-makers, consumers and professionals make good decisions about cancer screening in future.
The identification, prevention and management of chronic disease risk factors and understanding impact on clinical outcomes is fundamental to improving health and well-being. The program of work encapsulated in this application utilises a number of research methods to advance our understanding and provide new directions for cardiovascular disease prevention and management.
Improving Outcomes For Cancer Patients By Targeting The Epigenome
Funder
National Health and Medical Research Council
Funding Amount
$2,258,892.00
Summary
The most commonly mutated proteins in cancer involve so called epigenetic regulators, a class of proteins that regulate access to our DNA to control gene expression, DNA repair and replication. We and others have recently developed a variety of drugs to help inhibit the aberrant activity of these epigenetic proteins. My research will focus on ways to improve the efficacy of these existing drugs and find new epigenetic therapies to improve the survival of patients with a broad range of cancers.
Improving Interpreting For Dementia Assessments: The MINDSET Study
Funder
National Health and Medical Research Council
Funding Amount
$271,586.00
Summary
The MINDSET Study aims to improve the quality of communication in an interpreter mediated cognitive assessment for dementia. Working with interpreters, clinicians, culturally and linguistically diverse people with dementia, and their carers we will co-design, trial, and implement national online training targeted at interpreters. This training will enable interpreters to be prepared and confident in performing their role impartially, effectively, and accurately.
This Centre of Research Excellence will translate the best available evidence to improve cancer outcomes through better management of infections in cancer patients, a rapidly growing group. We will establish new research networks to detect emerging multi resistant infections, develop guidelines on how to manage them, implement locally successful programs that have been shown to save lives nationally and validate new practice changing immune, bioinformatics and diagnostic technologies.
Circulating Tumour DNA To Monitor Treatment Response And Resistance In Chronic Lymphocytic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$876,950.00
Summary
Many cancers shed small amounts of DNA (ctDNA) into the patient’s bloodstream and recent advances in genomic technologies now allow levels of ctDNA to be accurately measured in the blood. Changes in ctDNA levels have potential to be used as specific markers of disease progression and/or response to cancer therapy. This project will evaluate if ctDNA can be used to monitor treatment responses and individualise treatment decisions in patients with chronic lymphocytic leukaemia.
Investigating Treatments And Biomarkers Of Brain Concussion
Funder
National Health and Medical Research Council
Funding Amount
$428,065.00
Summary
Concussions are a serious and common international health concern, and repeated concussions can have severe long-term consequences on the brain. This project will aim to provide insight into this poorly understood disease projects and ultimately improve the management of concussions in human patients.
National Implementation Trial Of An Evidence-informed Workplace Sitting Reduction Intervention
Funder
National Health and Medical Research Council
Funding Amount
$624,575.00
Summary
Long periods of sitting time are bad for health. We will conduct a three-year national trial with five workplace-health partner organizations testing a website-delivered program for reducing sitting time at work. It will be offered to over 10,000 desk-based employees. We will determine the impacts of the program as well as refinements needed for full-scale dissemination: uptake of the program, how well it can be delivered on a large scale, its impact on sitting time, and the costs involved.